Canigen DHPPi Lyophilisate for Suspension for Injection for Dogs

Страна: Велика Британія

мова: англійська

Джерело: VMD (Veterinary Medicines Directorate)

Активний інгредієнт:

Canine adenovirus, Canine distemper virus, Canine parainfluenza virus, Canine parvovirus

Доступна з:

MSD Animal Health UK Limited

Код атс:

QI07AD04

ІПН (Міжнародна Ім'я):

Canine adenovirus, Canine distemper virus, Canine parainfluenza virus, Canine parvovirus

Фармацевтична форма:

Powder for suspension for injection

Тип рецепту:

POM-V - Prescription Only Medicine – Veterinarian

Терапевтична група:

Dogs

Терапевтична области:

Live Viral Vaccine

Статус Авторизація:

Authorized

Дата Авторизація:

2005-10-20

Характеристики продукта

Revised: April 2023
AN: 01767/2022
Page 1 of 7
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Canigen DHPPi lyophilisate for suspension for injection for dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 ml dose contains:
ACTIVE SUBSTANCES:
Live canine distemper virus (CDV), strain Onderstepoort

10
4.0
TCID
50
*
Live canine adenovirus type 2 (CAV
2
), strain Manhattan LPV3

10
4.0
TCID
50
*
Live canine parvovirus (CPV), strain 154

10
7.0
TCID
50
*
Live canine parainfluenza virus (CPi), strain Cornell

10
5.5
TCID
50
*
* TCID
50
= median Tissue Culture Infective Dose
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Lyophilisate for suspension for injection.
Off-white or cream-coloured pellet.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For active immunisation of dogs to prevent mortality and clinical
signs caused by
canine distemper virus infection. To reduce clinical signs of
infectious hepatitis and
viral excretion due to canine adenovirus type 1 infection. To prevent
mortality, clinical
signs and viral excretion following canine parvovirus infection. To
reduce clinical signs
and viral excretion caused by canine parainfluenza virus infection and
to reduce
clinical signs of respiratory disease and viral excretion following
adenovirus type 2
infection.
Onset of immunity:
Canine distemper virus, canine adenovirus and canine parvovirus
vaccine
components: 1 week.
Canine parainfluenza virus vaccine component: 4 weeks.
Revised: April 2023
AN: 01767/2022
Page 2 of 7
Duration of immunity:
Canine distemper virus, canine adenovirus and canine parvovirus
vaccine
components: 3 years.
The duration of immunity for the canine parainfluenza virus component
has not been
demonstrated, but an anamnestic response is produced in dogs given a
revaccination
one year after basic vaccination. Annual revaccination with the canine
parainfluenza
virus vaccine component is recommended.
4.3
CONTRAINDICATIONS